Oticara’s Intranasal Steroid Cream Achieves Phase 2 Success in Post-Surgical Chronic Rhinosinusitis
Oticara’s intranasal steroid cream met primary endpoints in a phase 2 trial for post-surgicalchronic rhinosinusitis(CRS), showing significant improvements in 4CSS and SNOT-22 scores by week 3. The in-office treatment provided rapid, durable symptom relief and was well-tolerated, with no severe adverse events reported. The late-breaking presentation, delivered by Professor Anders Cervin, MD, PhD, FRACS, will highlight findings from the Phase 2 trial of Oticara’s proprietary nasal-mucosa-optimized steroid cream. The treatment is an Ear, Nose and Throat (ENT) physician-administered cream designed specifically for the nasal mucosa, with clinical data demonstrating single-dose, durable relief for hard-to-treat post-surgical CRS patients. “We are honored to have been selected to present our recent clinical study results at AAO-HNSF,” said Chris Marich, Founder and Chief Executive Officer of Oticara. “We see a clear need for new options that can deliver durable benefits and reduce reliance on systemic steroids in hard-to-treat CRS patients with an easy-to-administer single-dose treatment.” Full data from the Phase 2 OT-007B trial will be presented during the meeting and the scientific paper is undergoing peer review by the American Academy of Otolaryngology–Head and Neck Surgery Foundation.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!